Dual-Motif Radiolabeled Compound for CAIX Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging agents for carbonic anhydrase IX (CAIX) in renal cell carcinoma face challenges such as low tumor uptake, high non-specific organ accumulation, and slow pharmacokinetics, particularly due to the similarity of CAIX isoforms and limitations of optical agents in tissue penetration and kidney uptake.
Innovation Solution
Development of a dual-motif, low-molecular-weight radiolabeled compound XYIMSR-01, conjugated with a metal chelator like DOTA, which targets two separate sites on CAIX, allowing for rapid clearance from non-target tissues and enhanced tumor specificity using PET/SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiolabeled antibodies are used to target CAIX, then tumor targeting capability is achieved, but blood and non-target tissue clearance is slow (2-5 days or longer)
Solution Approach 1:
The patent changes the molecular weight parameter from high (antibodies) to low (small molecule compounds), which fundamentally alters the pharmacokinetic profile. This parameter change enables both rapid tumor penetration and fast renal clearance, resolving the contradiction between targeting capability and clearance time.
2Productivity
If low-molecular-weight CAIX ligands are used, then faster pharmacokinetics and higher specific signal are achieved, but tumor uptake is low and off-target accumulation is significant
Solution Approach 1:
The patent segments the CAIX enzyme structure into two distinct binding sites: the active site (zinc-binding domain) and an additional allosteric site. The bivalent ligand simultaneously targets both sites, with the first motif binding to the active site and the second motif binding to the additional site. This segmentation strategy enhances tumor specificity while maintaining fast pharmacokinetics.
Solution Approach 2:
The patent merges two separate binding motifs into a single bivalent ligand molecule. This combining approach creates a compound that binds more strongly and specifically to CAIX by engaging multiple sites simultaneously, thereby improving tumor uptake and specificity while retaining the advantages of low-molecular-weight compounds.
3Measurement precision
If optical imaging agents are used, then CAIX expression can be detected, but light emission is substantially attenuated through tissue
Solution Approach 1:
The patent replaces optical detection (photons) with nuclear imaging detection (gamma rays or positrons). This substitution of the detection mechanism eliminates the problem of tissue attenuation, as ionizing radiation used in PET/SPECT imaging can penetrate deep into tissues without significant attenuation, enabling reliable detection of CAIX expression regardless of tumor depth.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dual-motif compound demonstrates significant and specific tumor uptake with rapid clearance from non-target tissues, including kidneys, enabling effective imaging of CAIX-expressing tumors with improved pharmacokinetics compared to previous agents.
Implementation Method 1
B is a metal chelating moiety optionally comprising a metal or a radiometal, or a halogenated or radio-halogenated prosthetic group
Data Source
AI summary
Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.